Business Insider
My Markets Watchlist
Markets Stocks

ResMed Inc. Stock , RMD

251.41 -0.87 -0.34%
12:14:59 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Monday morning 06/09/2025 the ResMed Inc. share started trading at the price of $252.00. Compared to the closing price on Friday 06/06/2025 on BTT of $252.28, this is a drop of 0.11%. There are 146.63 M shares outstanding in ResMed Inc., which values the company at $30.33 B.
Is ResMed stock a Buy, Sell or Hold? ResMed stock has received a consensus rating of buy. The average rating score is and is based on 24 buy ratings, 9 hold ratings, and 0 sell ratings.
What was the 52-week low for ResMed stock? The low in the last 52 weeks of ResMed stock was 179.50. According to the current price, ResMed is 140.06% away from the 52-week low.
What was the 52-week high for ResMed stock? The high in the last 52 weeks of ResMed stock was 262.62. According to the current price, ResMed is 95.73% away from the 52-week high.
What are analysts forecasts for ResMed stock? The 33 analysts offering price forecasts for ResMed have a median target of 221.91, with a high estimate of 290.00 and a low estimate of 160.00. The median estimate represents a 113.29 difference from the last price of 251.41.

ResMed Stock Snapshot

251.35
Bid
4.00
Bid Size
251.56
Ask
10.00
Ask Size
6/9/2025
Date
12:14 PM
Time
6,602.00
Volume
252.28
Prev. Close
252.00
Open
36.98 B
Market Cap in USD
146.63 M
Number of Shares
146.63 M
Total Number of Shares
248.82
Day Low
252.14
Day High
251.41
179.50
52 Week Low
262.62
52 Week High
251.41
1.92
Dividend in USD
1.00
Dividend Yield
27.66
P/E Ratio
99.29
Free Float in %
6.92
EPS in USD
33.11
Book Value per Share in USD
9.50
Cash Flow per Share in USD

Historical Prices for ResMed

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

ResMed Analyst Data

Total Analysts: 33
Buy Ratings: 24 Neutral Ratings: 9 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 160.00 Median: 221.91 Highest: 290.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

ResMed Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
04/24/25 RBC Capital Markets
Maintained Hold $255
04/24/25 UBS
Maintained Buy $285
04/24/25 J.P. Morgan
Maintained Buy $290
04/24/25 Piper Sandler
Maintained Hold $248
03/05/25 Citigroup Corp.
Upgraded to Buy
03/05/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $240
01/31/25 J.P. Morgan
Maintained Buy $286
01/31/25 Piper Sandler
Maintained Hold $260
01/31/25 Needham & Company, LLC
Maintained Hold
07/23/24 RBC Capital Markets
Maintained Hold $204
06/25/24 Oppenheimer & Co. Inc.
Downgraded to Hold
06/24/24 Citigroup Corp.
Downgraded to Hold
06/24/24 Needham & Company, LLC
Maintained Buy $236
04/26/24 Oppenheimer & Co. Inc.
Maintained Buy $200
04/26/24 RBC Capital Markets
Maintained Hold $200
04/26/24 Needham & Company, LLC
Maintained Buy $236
04/01/24 Needham & Company, LLC
Maintained Buy $224
03/27/24 Mizuho
Maintained Buy $215
01/30/24 Oppenheimer & Co. Inc.
Maintained Buy $205
01/30/24 Mizuho
Maintained Buy $215
01/26/24 Mizuho
Maintained Buy $195
01/25/24 UBS
Maintained Hold $180
01/25/24 RBC Capital Markets
Maintained Hold $182
01/25/24 Needham & Company, LLC
Maintained Buy $215
01/09/24 J.P. Morgan
Maintained Buy $195
10/31/23 Mizuho
Maintained Buy $160
10/27/23 Morgan Stanley
Upgraded to Buy $169
10/16/23 Oppenheimer & Co. Inc.
Maintained Buy $175
10/12/23 RBC Capital Markets
Downgraded to Hold $202
09/29/23 Wolfe Research
Downgraded to Hold
09/18/23 Bank of America Merrill Lynch
Maintained Buy $230
09/13/23 Mizuho
Maintained Buy $180
09/06/23 Needham & Company, LLC
Upgraded to Buy $180
09/05/23 UBS
Downgraded to Hold $170
08/14/23 RBC Capital Markets
Maintained Buy $273
08/04/23 RBC Capital Markets
Maintained Buy $284
08/04/23 Bank of America Merrill Lynch
Maintained Buy $250
08/01/23 RBC Capital Markets
Upgraded to Buy $284

ResMed Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 5,124 5,534 5,935 6,328 7,011
Dividend - - 2.59 2.77 -
Dividend Yield (in %) 0.91 % 1.02 % 1.03 % 1.10 % -
EPS 9.49 10.58 11.62 12.34 13.50
P/E Ratio 26.58 23.86 21.72 20.44 18.69
EBIT 1,716 1,896 2,076 2,191 2,417
EBITDA 1,870 2,060 2,242 2,284 2,292
Net Profit 1,377 1,520 1,672 1,761 1,906
Net Profit Adjusted 1,399 1,552 1,706 1,795 1,931
Pre-Tax Profit 1,701 1,903 2,095 2,203 2,414
Pre-Tax Profit Reported 1,694 1,939 2,119 2,182 -
EPS (Non-GAAP) ex. SOE 9.49 10.58 11.62 12.34 13.50
EPS (GAAP) 9.32 10.33 11.41 12.09 13.33
Gross Income 3,056 3,334 3,597 3,852 4,235
Cash Flow from Investing -144 -170 -132 -101 -
Cash Flow from Operations 1,503 1,595 1,732 1,863 -
Cash Flow from Financing -685 -622 -523 -394 -
Cash Flow per Share 10.06 10.83 12.07 - -
Free Cash Flow 1,448 1,470 1,586 1,597 1,468
Free Cash Flow per Share 10.15 10.38 11.26 12.14 -
Book Value per Share 39.35 46.00 53.72 57.28 -
Net Debt -386 -1,248 -2,228 -3,110 -
Research & Development Exp. 333 358 381 424 486
Capital Expenditure 99 122 129 179 265
Selling, General & Admin. Exp. 999 1,067 1,136 1,196 1,332
Shareholder’s Equity 5,909 6,909 8,088 8,269 -
Total Assets 7,638 8,585 9,753 10,407 -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 06/30/25 		Next Year
ending 06/30/26
Earnings Estimates
No. of Analysts - 13 10 24 24
Average Estimate - 2.478 USD 2.468 USD 9.492 USD 10.575 USD
Year Ago - 1.989 USD 2.120 USD 6.944 USD -
Publish Date - 7/31/2025 10/23/2025 - -
Revenue Estimates
No. of Analysts - 14 10 25 25
Average Estimate - 1,326 USD 1,317 USD 5,124 USD 5,534 USD
Year Ago - 1,223 USD 1,225 USD 4,685 USD -
Publish Date - 7/31/2025 10/23/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 4,685.30 4,222.99 3,578.13 3,196.83 2,957.01 2,606.57 2,340.20
Change of sales in % 10.95 18.02 11.93 8.11 13.44 11.38 13.23
Gross profit on sales 2,608.78 2,313.64 1,993.23 1,808.02 1,687.69 1,461.65 1,315.78
Gross profit on sales change in % 12.76 16.07 10.24 7.13 15.47 11.09 13.90
Operating income 1,384.12 1,152.00 1,000.29 912.35 809.06 635.99 560.26
Operating income change in % 20.15 15.17 9.64 12.77 27.21 13.52 22.67
Income before tax 1,264.80 1,101.66 960.48 883.66 733.09 518.85 521.31
Income before tax change in % 14.81 14.70 8.69 20.54 41.29 -0.47 24.49
Income after tax 1,020.95 897.56 779.44 474.51 621.67 404.59 315.59
Income after tax change in % 13.75 15.15 64.26 -23.67 53.65 28.20 -7.80

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 2,008.35 2,621.81 1,735.10 1,842.45 2,090.35 2,035.49 1,004.94
Long-term liabilities per share 7.47 12.67 7.14 6.39 10.27 10.30 3.46
Equity 4,864.04 4,129.90 3,360.75 2,885.68 2,497.03 2,072.19 2,058.98
Equity change in % 17.78 22.89 16.46 15.56 20.50 0.64 5.04
Balance sheet total 6,872.39 6,751.71 5,095.85 4,728.13 4,587.38 4,107.68 3,063.92
Balance sheet total change in % 1.79 32.49 7.78 3.07 11.68 34.07 -11.66

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 31.75 28.64 24.33 21.83 20.30 18.04 16.25
P/E ratio (year end quote, basic EPS) 27.66 35.90 39.55 76.09 44.98 43.58 47.26
P/E ratio (year end quote, diluted EPS) 27.66 35.90 39.55 76.09 44.98 43.58 47.26
Dividend yield in % 1.00 0.81 0.80 0.63 0.81 1.21 1.35
Equity ratio in % 70.78 61.17 65.95 61.03 54.43 50.45 67.20
Debt ratio in % 29.22 38.83 34.05 38.97 45.57 49.55 32.80

ResMed Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
FARRELL PETER C 06/03/2025 2,000.00 69,218.00 247.32 Sell No
Sandercock Brett 06/01/2025 1,000.00 85,283.00 243.78 Sell No
Sandercock Brett 05/21/2025 3,644.00 86,283.00 244.59 Sell No
De Witte Jan 05/19/2025 2,000.00 5,806.00 243.47 Sell No
FARRELL PETER C 05/06/2025 2,000.00 71,218.00 242.25 Sell No
Sandercock Brett 04/07/2025 1,000.00 89,864.00 215.58 Sell No
Farrell Michael J. 04/06/2025 8,009.00 455,472.00 209.85 Sell No
Farrell Michael J. 04/06/2025 8,009.00 463,482.00 101.64 Buy No
FARRELL PETER C 04/01/2025 2,000.00 73,218.00 219.74 Sell No
Rider Michael J 03/31/2025 64.00 8,846.00 222.86 Sell No
Sandercock Brett 03/09/2025 1,000.00 90,864.00 230.36 Sell No
Ghoshal Kaushik 03/09/2025 9,745.00 9,725.00 239.31 Sell No
Ghoshal Kaushik 03/09/2025 5,882.00 19,470.00 211.76 Buy No
Ghoshal Kaushik 03/09/2025 3,589.00 13,588.00 146.34 Buy No
Ghoshal Kaushik 03/09/2025 105.00 9,999.00 211.76 Buy No
Ghoshal Kaushik 03/09/2025 169.00 9,894.00 146.34 Buy No
Farrell Michael J. 03/06/2025 8,009.00 455,472.00 229.20 Sell No
Farrell Michael J. 03/06/2025 8,009.00 463,481.00 101.64 Buy No
Sandercock Brett 02/09/2025 1,000.00 91,864.00 238.98 Sell No
Farrell Michael J. 02/06/2025 8,009.00 455,472.00 236.77 Sell No
Farrell Michael J. 02/06/2025 8,009.00 463,481.00 101.64 Buy No
FARRELL PETER C 02/04/2025 2,000.00 77,218.00 242.11 Sell No
Sandercock Brett 01/07/2025 1,000.00 92,864.00 234.04 Sell No
FARRELL PETER C 01/01/2025 2,000.00 79,218.00 230.99 Sell No
Sandercock Brett 12/08/2024 1,000.00 93,864.00 244.23 Sell No

ResMed Dividend Calendar

Date Name Dividend *yield Currency
2024 ResMed Inc. 1.92 1.00 USD
2023 ResMed Inc. 1.76 0.81 USD
2022 ResMed Inc. 1.68 0.80 USD
2021 ResMed Inc. 1.56 0.63 USD
2020 ResMed Inc. 1.56 0.81 USD
2019 ResMed Inc. 1.48 1.21 USD
2018 ResMed Inc. 1.40 1.35 USD
2017 ResMed Inc. 1.32 1.70 USD
2016 ResMed Inc. 1.20 1.90 USD
2015 ResMed Inc. 1.12 1.99 USD
2014 ResMed Inc. 1.00 1.98 USD
2013 ResMed Inc. 0.68 1.51 USD
2012 ResMed Inc. 0.00 0.00 USD
2011 ResMed Inc. 0.00 0.00 USD
2010 ResMed Inc. 0.00 0.00 USD
2009 ResMed Inc. 0.00 0.00 USD
*Yield of the Respective Date

ResMed Calendar

Event Estimate Info Date
Earnings Report 2.478 USD Q4 2025 Earnings Release 07/31/2025
Earnings Report 2.468 USD Q1 2026 Earnings Release 10/23/2025
Earnings Report 2.630 USD Q2 2026 Earnings Release 01/22/2026
Earnings Report 2.678 USD Q3 2026 Earnings Release 04/23/2026

ResMed Past Events

Event Actual EPS Info Date
Earnings Report 2.480 USD Q3 2025 Earnings Release 04/23/2025
Earnings Report 2.340 USD Q2 2025 Earnings Release 01/30/2025
Annual General Meeting 6.920 USD Annual General Meeting 11/21/2024
Earnings Report 2.110 USD Q1 2025 Earnings Release 10/24/2024
Earnings Report 1.980 USD Q4 2024 Earnings Release 08/01/2024
Earnings Report 2.040 USD Q3 2024 Earnings Release 04/25/2024
Earnings Report 1.420 USD Q2 2024 Earnings Release 01/24/2024
Annual General Meeting 6.090 USD Annual General Meeting 11/16/2023
Earnings Report 1.490 USD Q1 2024 Earnings Release 10/26/2023
Earnings Report 1.560 USD Q4 2023 Earnings Release 08/03/2023
Earnings Report 1.580 USD Q3 2023 Earnings Release 04/27/2023
Earnings Report 1.530 USD Q2 2023 Earnings Release 01/26/2023
Annual General Meeting 5.300 USD Annual General Meeting 11/17/2022
Earnings Report 1.430 USD Q1 2023 Earnings Release 10/27/2022
Earnings Report 1.330 USD Q4 2022 Earnings Release 08/11/2022
Earnings Report 1.220 USD Q3 2022 Earnings Release 04/28/2022
Earnings Report 1.370 USD Q2 2022 Earnings Release 01/27/2022

ResMed Profile

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

ResMed Management

Name Job
Michael J. Farrell Chairman & Chief Executive Officer
Peter C. Farrell Chairman-Emeritus
Bobby Ghoshal Chief Commercial Officer-SaaS
Jim Ellis Chief Compliance Officer
Brett A. Sandercock Chief Financial Officer
Alastair Robertson Chief Information Officer
Todd Friedman Chief Information Security Officer
Sallilyn Schwartz Chief Investor Relations Officer
Yvonne-Katrin Pucknat Chief Marketing Officer
Carlos M. Nunez Chief Medical Officer
Vered Keisar Chief People Officer
Justin G. Leong Chief Product Officer
Dawn Haake Chief Quality Officer
Michael Fliss Chief Revenue Officer
Hemanth Reddy Chief Strategy Officer
Shane Azzi Chief Supply Chain Officer
Timothy Smokoff General Manager-Home Health & Hospice
John B. Hernandez Independent Director
Carol J. Burt Independent Director
Richard Sulpizio Independent Director
Karen Ruth Drexler Independent Director
Christopher J. DelOrefice Independent Director
Desney Tan Independent Director
Harjit Gill Independent Director
Jan D. De Witte Independent Director
Ronald R. Taylor Lead Independent Director
Michael Rider Secretary & Chief Legal Officer
Mike Ott Senior Manager-Investor Relations
Lucile Blaise Senior VP-Strategy & Business Development
Geoff Neilson Senior Vice President-Global Supplier Alliance